We are pleased that negotiators eliminated problematic language on technology transfer in the global action plan on AMR. Governments have a responsibility to regulate industry, and this can include mandates on sharing access to intellectual property rights, data, biologic resources and manufacturing know-how. To illustrate state practice on this issue, KEI has provided two relevant briefing notes, KEI Briefing note 2024:2: and KEI Briefing Note 2024:3, on this topic. These two briefing notes illustrate the range of measures that can and are used to mandate the transfer of technology for medical products, including antimicrobial medicines.